Avacopan Patent Expiration
Avacopan is Used for treating severe active ANCA-associated vasculitis in adult patients in combination with standard therapy. It was first introduced by Chemocentryx Inc
Avacopan Patents
Given below is the list of patents protecting Avacopan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tavneos | US11603356 | Amorphous form of a complement component C5a receptor | Nov 27, 2039 | Chemocentryx |
| Tavneos | US11951214 | Capsule formulations | Nov 27, 2039 | Chemocentryx |
| Tavneos | US8906938 | C5aR antagonists | Jan 06, 2034 | Chemocentryx |
| Tavneos | US8445515 | C5aR antagonists | Feb 03, 2031 | Chemocentryx |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Avacopan's patents.
Latest Legal Activities on Avacopan's Patents
Given below is the list recent legal activities going on the following patents of Avacopan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eCofC Notification | 05 Aug, 2025 | US11603356 |
| Email Notification | 05 Aug, 2025 | US11603356 |
| Recordation of Patent eCertificate of Correction | 05 Aug, 2025 | US11603356 |
| Patent eCofC Notification | 05 Aug, 2025 | US11603356 |
| Post Issue Communication - Certificate of Correction | 16 Jul, 2025 | US11603356 |
| Mail Pub Notice re 312 amendment | 07 Jul, 2025 | US11603356 |
| Email Notification | 07 Jul, 2025 | US11603356 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 03 Jul, 2025 | US11603356 |
| Post Issue Communication - Certificate of Correction Denied | 03 Jul, 2025 | US11603356 |
| Notice of Final Determination -Eligible | 03 Apr, 2025 | US8445515 |
Avacopan's Family Patents
